1182 studies found for:    "Pancreatic Neoplasms"
Show Display Options
Rank Status Study
1 Not yet recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
2 Completed Eribulin Mesylate as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Pancreatic Cancer;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: eribulin mesylate
3 Recruiting Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Conditions: Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms
Interventions: Drug: Modified FOLFIRINOX;   Radiation: Stereotactic Body Radiotherapy (SBRT)
4 Active, not recruiting RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
5 Completed CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
6 Active, not recruiting Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: sorafenib tosylate;   Drug: gemcitabine hydrochloride
7 Completed UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 7-hydroxystaurosporine;   Drug: gemcitabine hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Completed Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
9 Completed Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: cetuximab;   Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Drug: erlotinib hydrochloride
10 Completed Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Conditions: Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Procedure: conventional surgery;   Other: immunohistochemistry staining method;   Genetic: protein expression analysis;   Procedure: biopsy;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Unknown  Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Conditions: Acinar Cell Carcinoma of Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Pancreatic Carcinoma Recurrent;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Pancreatic Carcinoma Stage III
Interventions: Drug: dasatinib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Other: immunohistochemistry staining method
12 Unknown  Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Conditions: Adenocarincoma of Pancreas;   Stage III Pancreatic Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: 5-fluorouracil;   Drug: glutathione;   Drug: calcium and magnesium;   Procedure: Chemotherapy;   Procedure: Chemoprotection;   Procedure: Complementary and alternative therapy
13 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Completed Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Conditions: Recurrent Colon Cancer;   Extensive Stage Small Cell Lung Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage I Pancreatic Cancer;   Stage II Non-Small Cell Lung Cancer;   Stage IVB Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Colon Cancer;   Stage IVA Pancreatic Cancer
Interventions: Drug: Detox-B adjuvant;   Drug: ras peptide cancer vaccine
15 Recruiting Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Interventions: Drug: Gemcitabine and cisplatin;   Drug: Gemcitabine / Cisplatin
16 Terminated Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Intervention: Drug: RTA 402
17 Recruiting Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Intervention: Drug: Gemcitabine with escalating ascorbic acid
18 Completed Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: bryostatin 1;   Other: pharmacological study
19 Completed Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Other: laboratory biomarker analysis
20 Completed Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Conditions: Pancreatic Cancer;   Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: sorafenib tosylate;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study;   Other: mass spectrometry;   Other: liquid chromatography;   Genetic: polymorphism analysis;   Genetic: polymerase chain reaction

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years